Your browser doesn't support javascript.
Analysis of SARS-CoV-2 antibodies in COVID-19 convalescent blood using a coronavirus antigen microarray.
de Assis, Rafael R; Jain, Aarti; Nakajima, Rie; Jasinskas, Algis; Felgner, Jiin; Obiero, Joshua M; Norris, Philip J; Stone, Mars; Simmons, Graham; Bagri, Anil; Irsch, Johannes; Schreiber, Martin; Buser, Andreas; Holbro, Andreas; Battegay, Manuel; Hosimer, Philip; Noesen, Charles; Adenaiye, Oluwasanmi; Tai, Sheldon; Hong, Filbert; Milton, Donald K; Davies, D Huw; Contestable, Paul; Corash, Laurence M; Busch, Michael P; Felgner, Philip L; Khan, Saahir.
  • de Assis RR; Department of Physiology and Biophysics, School of Medicine, University of California, Irvine, CA, USA.
  • Jain A; Department of Physiology and Biophysics, School of Medicine, University of California, Irvine, CA, USA.
  • Nakajima R; Department of Physiology and Biophysics, School of Medicine, University of California, Irvine, CA, USA.
  • Jasinskas A; Department of Physiology and Biophysics, School of Medicine, University of California, Irvine, CA, USA.
  • Felgner J; Department of Physiology and Biophysics, School of Medicine, University of California, Irvine, CA, USA.
  • Obiero JM; Department of Physiology and Biophysics, School of Medicine, University of California, Irvine, CA, USA.
  • Norris PJ; Vitalant Research Institute, San Francisco, CA, USA.
  • Stone M; Department of Laboratory Medicine, University of California, San Francisco, CA, USA.
  • Simmons G; Vitalant Research Institute, San Francisco, CA, USA.
  • Bagri A; Department of Laboratory Medicine, University of California, San Francisco, CA, USA.
  • Irsch J; Vitalant Research Institute, San Francisco, CA, USA.
  • Schreiber M; Department of Laboratory Medicine, University of California, San Francisco, CA, USA.
  • Buser A; Cerus Corporation, Concord, CA, USA.
  • Holbro A; Cerus Corporation, Concord, CA, USA.
  • Battegay M; Department of Surgery, Oregon Health & Science University, Portland, OR, USA.
  • Hosimer P; Division of Infectious Diseases & Hospital Epidemiology, University Hospital Basel, University of Basel, Basel, Switzerland.
  • Noesen C; Department of Surgery, Oregon Health & Science University, Portland, OR, USA.
  • Adenaiye O; Division of Infectious Diseases & Hospital Epidemiology, University Hospital Basel, University of Basel, Basel, Switzerland.
  • Tai S; Ortho Clinical Diagnostics, Rochester, NY, USA.
  • Hong F; Ortho Clinical Diagnostics, Rochester, NY, USA.
  • Milton DK; Institute for Applied Environmental Health, School of Public Health, University of Maryland, College Park, MD, USA.
  • Davies DH; Institute for Applied Environmental Health, School of Public Health, University of Maryland, College Park, MD, USA.
  • Contestable P; Institute for Applied Environmental Health, School of Public Health, University of Maryland, College Park, MD, USA.
  • Corash LM; Institute for Applied Environmental Health, School of Public Health, University of Maryland, College Park, MD, USA.
  • Busch MP; Department of Physiology and Biophysics, School of Medicine, University of California, Irvine, CA, USA.
  • Felgner PL; Ortho Clinical Diagnostics, Rochester, NY, USA.
  • Khan S; Cerus Corporation, Concord, CA, USA.
Nat Commun ; 12(1): 6, 2021 01 04.
Article in English | MEDLINE | ID: covidwho-1007633
ABSTRACT
The current practice for diagnosis of COVID-19, based on SARS-CoV-2 PCR testing of pharyngeal or respiratory specimens in a symptomatic patient at high epidemiologic risk, likely underestimates the true prevalence of infection. Serologic methods can more accurately estimate the disease burden by detecting infections missed by the limited testing performed to date. Here, we describe the validation of a coronavirus antigen microarray containing immunologically significant antigens from SARS-CoV-2, in addition to SARS-CoV, MERS-CoV, common human coronavirus strains, and other common respiratory viruses. A comparison of antibody profiles detected on the array from control sera collected prior to the SARS-CoV-2 pandemic versus convalescent blood specimens from virologically confirmed COVID-19 cases demonstrates near complete discrimination of these two groups, with improved performance from use of antigen combinations that include both spike protein and nucleoprotein. This array can be used as a diagnostic tool, as an epidemiologic tool to more accurately estimate the disease burden of COVID-19, and as a research tool to correlate antibody responses with clinical outcomes.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 / Antibodies, Viral / Antigens, Viral Type of study: Diagnostic study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Limits: Humans Language: English Journal: Nat Commun Journal subject: Biology / Science Year: 2021 Document Type: Article Affiliation country: S41467-020-20095-2

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 / Antibodies, Viral / Antigens, Viral Type of study: Diagnostic study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Limits: Humans Language: English Journal: Nat Commun Journal subject: Biology / Science Year: 2021 Document Type: Article Affiliation country: S41467-020-20095-2